Multiple sclerosis therapy and Epstein-Barr virus antibody titres.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Multiple Sclerosis and Related Disorders

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.msard.2013.12.004PMID 25876475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

  2012cited by this paper
• Anti‐EBNA‐1 IgG is not a reliable marker of multiple sclerosis clinical disease activity

  2010cited by this paper
• Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis

  2010cited by this paper
• Epstein–Barr Virus and Multiple Sclerosis

  2010cited by this paper
• Epstein–Barr virus and multiple sclerosis

  2009cited by this paper
• Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI

  2009cited by this paper
• Quantitative PCR for Epstein–Barr virus DNA and RNA in multiple sclerosis

  2009cited by this paper
• Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

  2007cited by this paper
• Presence of Epstein–Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity

  2005cited by this paper
• Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

  2002cited by this paper
• Association between clinical disease activity and Epstein–Barr virus reactivation in MS

  2000cited by this paper

• Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies.

  2025cites this paper
• The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

  2025cites this paper
• In-depth analysis of serum antibodies against Epstein-Barr virus lifecycle proteins, and EBNA1, ANO2, GlialCAM and CRYAB peptides in patients with multiple sclerosis

  2024cites this paper
• Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.

  2023cites this paper
• Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study

  2023cites this paper
• Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy.

  2023cites this paper
• From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis

  2023cites this paper
• Markers of Epstein-Barr Virus Infection in Patients with Multiple Sclerosis

  2023cites this paper
• Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review.

  2023cites this paper
• Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment

  2022cites this paper
• Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study

  2022cites this paper
• Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis.

  2022cites this paper
• Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression.

  2022cites this paper
• Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.

  2020cites this paper
• The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging

  2019cites this paper
• A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis

  2017influential citation
• Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

  2015cites this paper
• Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis.

  2015cites this paper